Mark Copley, Sales Director for Copley Scientific, will discuss optimal testing strategies for the development of inhaled generic products at a specialist meeting in London, UK, in November. His invited presentation on 5 November 2013 is part of a pre-conference workshop on Bioequivalence for Inhaled Products, taking place ahead of the Management Forum Inhaled Drug Delivery (IDD) conference on 6 November. Both are being held at The Rembrandt Hotel, London.
The pre-conference workshop and the full conference programme include presentations from a number of leading industrialists and will cover current trends in inhaled drug delivery technology and regulation. To register for the workshop, or to find out more, please visit: www.managementforum.co.uk/pharmaceutical/eventid/2357#.UmaSHjuTxzp
Mark Copley’s presentation ‘Methodologies for in vitro bioequivalence testing of generic inhaled products’, will examine the laboratory tests that can be used to demonstrate that a generic product delivers equivalent clinical efficacy to a reference labelled drug. Generic inhaled drug development is a fast-growing area of the pharmaceutical industry. A primary focus is the commercialisation of inexpensive, efficient products for treating asthma and chronic obstructive pulmonary disease (COPD). Demonstrating bioequivalence through in vitro testing minimises the need for clinical trials, accelerating time to market and reducing development costs. Mark Copley will review the regulatory framework in this area and outline efficient testing strategies designed to fulfil the associated requirements.
As the world’s leading manufacturer and supplier of inhaler test equipment, Copley Scientific has a range of innovating new products to meet evolving requirements for both novel and generic inhaled product testing. Extensive company expertise supports the optimal application of these products to advance inhaled product development. To view the full range or to find out more visit: www.copleyscientific.com
Mark Copley, Sales Director for Copley Scientific, will present at the Management Forum workshop: Bioequivalence for Inhaled Products (5th November, London, UK).
About Copley Scientific
Copley Scientific is recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing, air sampling and aerosol characterisation.
Copley Scientific’s pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays; as well as tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories and transdermals.
Copley Scientific has offices in the UK and Switzerland. The company works in partnership with aerosol particle science experts MSP Corporation in North America, and also distributes MSP Corporation’s air sampling and aerosol characterisation products throughout Europe.
Serving the pharmaceutical and associated industries, Copley Scientific offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. www.copleyscientific.com
